December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Safety of Intravitreal Delivery of Adenovirusin Cynomolgus Monkeys
Author Affiliations & Notes
  • HS Rasmussen
    Clinical Research & Reg Affairs GenVec Inc Gaithersburg MD
  • WH Bee
    Sierra Biomedical Sparks NV
  • MC Wills
    Sierra Biomedical Sparks NV
  • RJ Munger
    Sierra Biomedical Sparks NV
  • RJ Durham
    GenVec Inc Gaithersburg MD
  • LL Wei
    GenVec Inc Gaitherburg MD
  • Footnotes
    Commercial Relationships    H.S. Rasmussen, GenVec, Inc. E; W.H. Bee, Sierra Biomedical E; M.C. Wills, Sierra Biomedical E; R.J. Munger, Sierra Biomedical E; Animal Ophthalmology Clinic E; R.J. Durham, GenVec, Inc. E; L.L. Wei, GenVec, Inc. E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1289. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      HS Rasmussen, WH Bee, MC Wills, RJ Munger, RJ Durham, LL Wei; Safety of Intravitreal Delivery of Adenovirusin Cynomolgus Monkeys . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1289.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Gene transfer offers a novel treatment for many types of ocular diseases. Adenovirus appears to be an efficient vector for delivery of therapeutic genes such as Pigment Epithelium-Derived Factor (PEDF). Studies were performed in Cynomolgus monkeys to evaluate the safety of intravitreal delivery of a second generation E1-, E4- and partial E3 deleted replication deficient vector, AdPEDF, as well as identify dose-limiting toxicity (DLT). Methods: Single invitreous injections of 1 x 108,1 x 109,1 x 1010, and 5 x 1010 particles (pu) and multiple injections of 1 x 109 were performed in one eye of 22 primates. No treatment or a comparable volume (50µl) of saline or vehicle was delivered to the contralateral eye. Safety was assessed by direct and indirect ophthalmologic examinations, electroretinography (ERG), tonometry, histopathology of the eye and observations of gross anatomy at necropsy. Results: Our findings showed no toxicity at the dose level of 1 x 108 pu (no adverse effect dose). At higher doses, dose-dependent inflammatory responses, ranging from minimal and reversible at a dose of 1 x 109 pu to moderate at a dose of 1 x 1010 pu and marked at a dose level of 5 x 1010 pu were observed. ERG responses were normal with doses of 1 x 108 pu and 1 x 109 pu. All control eyes were within normal limits. No systemic toxicities were observed at any dose level. Conclusion: Doses of 1 x 108 pu and 1 x 109 pu appear to be well tolerated in the monkey eye even after repeat dosing. Higher doses at 1 x 1010 pu and 5 x 1010 pu resulted in increasing levels of inflammation, the dose-limiting toxicity. These data identify a range of potential safe doses for a Phase I human clinical trial and methods to monitor for any potential adverse reactions; such a trial is currently being planned.

Keywords: 308 age-related macular degeneration • 419 gene transfer/gene therapy • 307 adenovirus 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.